NCT04901871View on ClinicalTrials.gov

Remimazolam Bolus for General Anesthesia

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

July 20, 2021

Study Completion Date

July 26, 2021

Conditions
Loss of Consciousness
Interventions
DRUG

0.02 mg/kg, age<65

Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.

DRUG

0.07 mg/kg, age<65

Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.

DRUG

0.12 mg/kg, age<65

Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.

DRUG

0.17 mg/kg, age<65

Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.

DRUG

0.22 mg/kg, age<65

Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.

DRUG

0.27 mg/kg, age<65

Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.

DRUG

0.02 mg/kg, age≥65

Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.

DRUG

0.07 mg/kg, age≥65

Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.

DRUG

0.12 mg/kg, age≥65

Remimazolam of 0.12 mg/kg will be infused in patients aged≥65

DRUG

0.17 mg/kg, age≥65

Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.

DRUG

0.22 mg/kg, age≥65

Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.

DRUG

0.27 mg/kg, age≥65

Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.

Trial Locations (1)

Unknown

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER